• Publications
  • Influence
Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist.
TLDR
It is concluded that KRH-594 is a specific and efficacious AT1 antagonist that may find its use in the treatment of human hypertension. Expand
In vitro pharmacological properties of KRH-594, a novel angiotensin II type 1 receptor antagonist.
TLDR
KRH-594 is a potent, specific and insurmountable AT1 receptor antagonist, demonstrating its high specificity for AT1 receptors. Expand
Effects of Spiraprilat, an Angiotensin‐Converting Enzyme Inhibitor, on Anesthetized Dogs in a New Model of Acute Left Ventricular Failure
TLDR
Data indicate that the beneficial effects of both inhibitors extended not only to LV function but also to myocardial energy metabolism in ALVF, and hemodynamic changes indicated establishment of stable ALFF of a moderate degree. Expand
Effect of carvedilol on venous return: a mechanism of reduction in blood pressure.
TLDR
The results indicate that the hypotensive effect of carvedilol mainly depends on the decrease in venous return rather than arterial vasodilation. Expand
Epidermal Growth Factor Prolongs Survival Time of Tumor‐bearing Mice
TLDR
The results suggest that prolongation of survival time by hEGF may result from the inhibition of tumor cell metastasis and EGF may play a role in preventing the metastasis of certain malignant neoplasms unrelated to its effects through the EGF receptor on tumor cells. Expand
Acyliminothiadiazoline derivatives: New, highly potent, and orally active angiotensin II receptor antagonists
Abstract Syntheses and pharmacological properties of a new series of acyliminothiadiazoline derivatives 1 are described. These compounds exhibited angiotensin II receptor antagonistic activities inExpand
Quantitative structure-activity relationships of benzoyliminothiadiazoline derivatives as angiotensin II receptor antagonists
Abstract Syntheses and biological activities of benzoyliminothiadiazoline derivatives which have potential affinities for angiotensin II receptor are described. The contributions of substituent (R 1Expand
Beta-blocking action of bopindolol, a new beta-blocker, and its active metabolites in open chest dogs.
TLDR
It is suggested that 18-502 is a more important active metabolite of bopindolol than 20-785 in in vivo conditions, though the metabolite20-785 is also a potent beta-blocker. Expand
...
1
2
...